CCCC: When protein degradation becomes a new class of oncologyC4 Therapeutics, Inc.BATS:CCCCTotoshkaTradesCCCC C4 Therapeutics builds a targeted protein degradation platform that destroys disease-causing proteins rather than just blocking them. A blocked protein remains in the cell and can find alternative pathways. A degraded protein ceases to exist. The company trades on Nasdaq. Finances - Q1 2026 The report was released on May 12. Revenue came in at $6.2 million, with a net loss of $25.1 million and EPS of -$0.20. Revenue beat the analyst consensus by 39 percent, while EPS exceeded expectations by 23 percent. R&D expenses were $24.6 million, and administrative expenses were $9.3 million. Cash and marketable securities reached $268.3 million, which management estimates is sufficient to fund operations through the end of 2028. During the quarter, the company received a $2 million milestone payment from Biogen. Cemsidomide: data that changes the narrative At the EHA 2026 congress, the company presented updated Phase 1 results from 73 patients with relapsed or refractory multiple myeloma. At the recommended Phase 2 dose (100 mcg), the overall response rate (ORR) was 53 percent, at 75 mcg it was 40 percent, and across the entire cohort it was 36 percent. Median duration of response reached 7.9 months, with seven patients still on treatment. In some patients, partial responses deepened over time to stringent complete responses, and two patients achieved MRD-negative status. This demonstrates not only a high response rate but also its durability in patients who had previously received a median of seven prior lines of therapy, including CAR-T and bispecific antibodies. Following the data release, the stock rose approximately 8 percent. In parallel, the company launched the Phase 2 MOMENTUM study and a Phase 1b study in combination with elranatamab. In 2027, another combination therapy program is planned to begin. Roche and partnership structure In April 2026, C4 Therapeutics signed a new agreement with Roche to jointly develop degrader-antibody conjugates (DAC). The company received an upfront payment of $20 million, with potential milestone payments exceeding $1 billion across two oncology targets. Partnerships with Roche, Biogen, Betta Pharma, and Merck KGaA confirm strong interest from major pharmaceutical companies in targeted protein degradation technology. Risks The company remains unprofitable and fully dependent on the successful development of its clinical programs. Following the discontinuation of CFT8919 outside China, investor focus is concentrated on cemsidomide. Regulatory risks, potential toxicity in broader patient populations, and possible study delays remain key uncertainties. An additional risk is the potential capital raise through the active S-3 registration of $400 million and a $125 million ATM program. Capital structure Institutional investors control 78.81 percent of the company's shares. Short interest stands at 21.31 percent of the float, with Days to Cover at approximately 9.5 days. In the event of strong clinical data or new partnership agreements, this creates potential for accelerated short covering and amplified upside movement. The analyst consensus remains Strong Buy with an average price target of approximately $13. Technicals - weekly timeframe On the weekly chart, a clean breakout above the multi-year descending trendline has been confirmed, accompanied by a surge in accumulation volume at historical lows, indicating aggressive institutional positioning. Indicators confirm the strength of the upward impulse. ADX has risen to 45.14, signaling the formation of a powerful trend. DI+ at 30.35 significantly exceeds DI- at 12.30, proving absolute buyer control. MACD is in an active growth phase and gives a buy signal. RSI remains in neutral territory, indicating no overheating and room for further upside. For position entry, a full retest of the broken support zone in the 2.75–2.85 optimal entry range is recommended. The final trigger will be the formation of a golden cross. The risk-to-reward ratio at current levels looks excellent. The first intermediate target is $10.94, with a final global target of $48.00. C4 Therapeutics combines several strong factors: a 53 percent ORR with a 7.9-month median duration of response in heavily pretreated patients, a new Roche partnership with potential payments exceeding $1 billion, a cash runway through 2028, and short interest above 21 percent that could amplify movement on positive catalysts.